Analysis for ZTS

📈 Growth & Financial Trajectory

Zoetis' trailing eight-quarter sequence shows revenue growth from about $2.22B in 2024 Q3 to $2.468B in 2026 Q2, an ~11% rise, with net income advancing from $631M to $691M despite a mid-period dip in 2025 Q4. The trend is positive but with volatility, particularly around 2025 Q4 trough.

💰 Margins & Cash Flow

Gross margins run around 70%–77%, with a cadence near 72%–73%. Operating margins sit in the mid‑30s, dipping briefly in 2025 Q4 before stabilizing near 33%–36% in 2026. Net income margin follows, holding roughly mid‑20s to low‑30s; 2025 Q4 was weaker. Operating cash flow is solid; investing/financing activities produce negative net cash flows in several periods, resulting in occasional net cash outflows despite healthy operating cash flow.

🛡️ Balance Sheet & Liquidity

Current assets exceed current liabilities, supporting a strong liquidity profile (current ratio well above 2x). Total assets run about $14–$15B with liabilities in the $9–$12B range and equity around $3–$5B, indicating moderate leverage and healthy coverage of near‑term obligations.

⚠️ Key Drivers & Risks

• Drivers: Global animal health demand, vaccines and companion‑animal wellness, and growth in developed and emerging markets.
• Risks: Margin pressure and quarterly volatility (notably around 2025 Q4), and currency/interest-rate sensitivity.